MENU
JAN 12, 2016 8:00 AM PST

WEBINAR: Combined Use of Multiple Particle Characterization Technologies to Evaluate Targeted Liposomal Formulations: Implications for General Nanoparticle Development

Speaker
  • Professor, Cardiovascular Medicine, University of Texas Health Science Center at Houston
    Biography
      Dr. Klegerman received a B.A. in chemistry from the University of Illinois at Chicago in 1968 and a Ph.D. in biochemistry from Loyola University of Chicago in 1984. For more than 30 years, he has conducted biomedical research focusing on immunochemistry, immunoassay development, and conjugation chemistry. For the past 20 years, Dr. Klegerman has been involved in a collaborative effort with cardiovascular researchers under the direction of Dr. David D. McPherson to develop targeted immunoliposomes for diagnosis and treatment of cardiovascular diseases, joining the group when they moved to The University of Texas Health Science Center in Houston, where he now is a professor in the Division of Cardiovascular Diseases. As part of this effort, Dr. Klegerman founded two companies to develop the echogenic liposome technology into clinical products.

      He is an author of 75 scientific papers, awardee of four patents, and co-editor of a textbook of pharmaceutical biotechnology (1992).

    Abstract
    January 12, 2016, 8:00am PT, 11:00am ET, 3:00pm GMT

    Targeted nanoparticle applications have become a major focus of translational development of both diagnostics and therapeutics for clinical use.  One of the oldest and best established nanoparticle formulations is liposomes, which can be readily targeted to tissue markers by chemical conjugation to ligands such as antibodies.  The cardiovascular research group at UTHealth has been exploring molecular targeting strategies for our intrinsically echogenic liposomes (ELIP) for nearly 25 years.  As part of this effort, we have developed evaluation methods for both conjugation and targeting efficiencies that rely on particle characterization techniques, especially the Beckman Coulter Multisizer.  This webinar will present the immunoblot assay (IBA) that measures IgG concentrations in the presence of liposomes.  We use the Multisizer to enumerate population based on size. We will present several sophisticated methods developed by us for determining targeting efficiency (TE), based on the CE and ELISA-measured antibody (Ab) binding affinity and binding efficiency.  The most informative measure of TE, however, is the specific TE, which is the product of the number of Ab molecules that actually bind to immobilized target molecules (determined by comparing the ELISA CE to the IBA CE) and the affinity.

    Learning Objectives:
    • Learn about the immunoblot assay (IBA) that measures immunoglobulin G (IgG) concentrations in the presence of liposomes.
    • Learn about sophisticated methods developed for determining targeting efficiency (TE), based on the CE and ELISA-measured antibody (Ab) binding affinity and binding efficiency 

    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAY 28, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 28, 2020 10:00 AM PDT
    DATE: May 28, 2020 TIME: 10:00am PT, 1:00pm ET Cardiac allograft rejection is a serious concern in transplant medicine, conferring an increased risk of acute graft failure and adverse patient...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    Loading Comments...
    Show Resources
    Attendees
    • See more